Key Highlights

  • Net loss per share was USD 0.05 against an estimate of a USD 0.21 loss.
  • Net patient service Revenue was USD 1.16 million, compared with USD 242 thousand.
  • Net loss was USD 2.18 million, compared with USD 5.89 million.
  • Cash and cash equivalents were USD 19.82 million at September 30, 2026.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) reported third quarter 2026 net patient service revenue of USD 1.16 million, compared with USD 242 thousand in the prior-year quarter. The net loss was USD 2.18 million, compared with USD 5.89 million.

Basic and diluted net loss per share was USD 0.05, compared with USD 0.27, against an estimate of a USD 0.21 loss. The company describes itself as a commercial-stage biopharmaceutical company that controls an ecosystem of companies focused on treating central nervous system disorders.

Third Quarter Results

Cost of patient services was USD 874 thousand, compared with USD 97 thousand. Research and Development expense was USD 1.81 million, compared with USD 1.43 million, and selling, general and administrative expense was USD 6.56 million, compared with USD 2.81 million.

Total operating expenses were USD 9.30 million, compared with USD 4.27 million, and the loss from operations was USD 8.15 million, compared with USD 4.02 million.

Total other income, net, was USD 5.97 million, compared with total other expense, net, of USD 1.87 million. The change in Fair Value of Warrant liabilities was a gain of USD 6.20 million, compared with a loss of USD 4.96 million, and interest expense was USD 239 thousand. Weighted average shares outstanding were 43,171,238, compared with 22,231,178.

Nine-Month Results

For the nine months ended September 30, 2026, net patient service revenue was USD 3.33 million, compared with USD 242 thousand. Total operating expenses were USD 22.72 million, compared with USD 11.84 million, and the loss from operations was USD 19.40 million, compared with USD 11.60 million.

The net loss was USD 20.13 million, compared with USD 28.98 million, and net loss per share was USD 0.53, compared with USD 1.54. Net cash provided by financing activities was USD 32.80 million, compared with USD 18.70 million.

Balance Sheet and Going Concern Disclosure

Cash and cash equivalents were USD 19.82 million at September 30, 2026, compared with USD 7.80 million at December 31, 2025. Total Assets were USD 27.82 million, compared with USD 12.96 million, and total liabilities were USD 29.80 million, compared with USD 28.89 million.

Current liabilities were USD 29.25 million, including warrant liabilities of USD 12.35 million. The stockholders' Deficit was USD 1.99 million, compared with USD 15.94 million, and the accumulated deficit was USD 327.02 million. The cover page reports 44,327,982 shares of common stock outstanding as of November 16, 2026.

The filing concludes that substantial doubt exists about the company's ability to continue as a going concern for at least twelve months from the date the financial statements were issued.

NRx Pharmaceuticals' Third Quarter 2026 Results in Review

NRx Pharmaceuticals reported third quarter 2026 net patient service revenue of USD 1.16 million and a net loss of USD 2.18 million, or USD 0.05 per share. The change in fair value of warrant liabilities was a gain of USD 6.20 million.

Cash and cash equivalents were USD 19.82 million at September 30, 2026, compared with USD 7.80 million at December 31, 2025, and the filing includes a going concern disclosure.